

IAP4 Rec'd PCT/PTO 05 DEC 2005

PCT

JENKINS
WILSON
& TAYLOR

Patent and Trademark Office

November 30, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 30, 2005.

Amy Yost

Date of Signature: November 30, 2005

RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

E. ERIC MILLS

BENTLEY J. OLIVE

*CHRIS PERKINS, PH.D.

*JAMES DALY IV, PH.D.

JEFFREY CHILDERS, PH.D.

P. ASHLEY DARDEN

*CHRISTOPHER B. LEE

TECHNICAL SPECIALIST
AMY ODENBAUGH, PH.D.

*LICENSED ONLY IN CA

**LICENSED ONLY IN KY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/551,395 for USE OF
PIPERAZINE PHENOTHIAZINE DERIVATIVES, OR A
PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER
THEREOF, IN THE MANUFACTURE OF A MEDICAMENT WITH
NEUROPROTECTOR AND/OR NEUROTROPHIC EFFECTS ON
CNS AND/OR PNS
Our Ref. No. 1386/22

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages) in duplicate;
3. Copies of cited references (25 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.

Registration No. 39,395

AAT/acy
Enclosures

Customer No: 25297

tel 919.493.8000
fax 919.419.0383

Jenkins, Wilson & Taylor, P.A.
JenkinsWilsonTaylor.com

University Tower, Suite 1400 | 3100 Tower Boulevard | Durham, North Carolina 27707

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 30, 2005.

PATENT

Amy Yost
Amy Yost
Date of Signature November 30, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Callinzot et al.

Serial No.: 10/551,395

Filed: September 29, 2005

Docket No.: 1386/22

For: USE OF PIPERAZINE PHENOTHIAZINE DERIVATIVES, OR A
PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, IN THE
MANUFACTURE OF A MEDICAMENT WITH NEUROPROTECTOR AND/OR
NEUROTROPHIC EFFECTS ON CNS AND/OR PNS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Serial No.: 10/551,395


Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 11/30/2005

By:




Arles A. Taylor, Jr.
Registration No. 39,395

AAT/acy

Enclosures

Customer No: 25297



FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Application No.:	10/551,395
Filing Date:	September 29, 2005
First Named Inventor:	Callizot et al.
Group:	To be assigned
Examiner:	To be assigned
Attorney Docket No.:	1386/22

List of Documents Cited by Applicant

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
	1	6,482,822	11/19/2002	Bigg et al.	
	2	6,057,373	5/2/2000	Fogel, Barry	
	3	3,320,245	5/16/1967	Wolf et al.	
	4	3,320,249	5/16/1967	Bernstein et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	5	WO 2004/096231	11/11/2004	Neuro 3D		
	6	WO 99/07356	2/18/1999	Univ. of South Fl. Research Foundation		
	7	EP 0615749 A2	9/21/94	Virginia Commonwealth Univ.		
	8	WO 01/78709 A2	10/25/2001	Minerva Biotech. Corp.		
	9	WO 96/04915	2/22/1996	Albert Einstein College		
	10	WO 00/24390	5/4/2000	Univ. of British Columbia		
	11	WO 02/22611	3/22/2002	Vertex Pharm. Inc.		
	12	WO 02/083656	10/24/2002	Harnett et al.		
	13	WO 00/32175	6/8/2000	Pfizer Product Inc.		
	14	WO 01/92240	12/6/2001	Dal-Housie Univ.		

	15	WO 03/062232	7/31/2003	Harnett et al.		
	16	WO 03/062388	7/31/2003	Regents of Univ. of Ca.		
OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.				T
	17	DAVIS ET AL. "Peripheral Diabetic Neuropathy Treated With Amitriptyline and Fluphenazine", <u>JAMA</u> , 238(21) : 2291-2292, Nov. 21, 1977.				
	18	MOSLEY ET AL. "Control of Diabetic Neuropathic Pain by Amitripty-Line (A) and Fluphenazine (F) in Mild Renal Failure" <u>J. of the Inter. Soc. of Nephrology</u> , 21(1) : 155, January 1982. ABSTRACT				
	19	GOMEZ-PEREZ, "Nortriptyline-Fluphenazine vs. Carbamazepine in the Symptomatic Treatment of Diabetic Neuropathy", <u>Archives of Med. Research</u> , 27(4) : 525-529, 1996.				
	20	GOMEZ-PEREZ ET AL., "Nortriptyline and Fluphenazine in the Symptomatic Treatment of diabetic Neuropathy. A Double-Blind Cross-Over Study", <u>Pain</u> , 23 : 395-400, 1985.				
	21	BATTLA ET AL., Clinical Trial of Amitriptyline and Fluphenazine in Diabetic Peripheral Neuropathy", <u>Southern Medical Journal</u> , 74(4) : 417-178, April 1981.				
	22	GOTTLIEH ET AL. "Depot Neuroleptics in the Treatment of Behavioral Disorders in Patients with Alzheimer's Disease", <u>JAGS</u> , 36 : 619-621, 1988.				
	23	VERMA ET AL. "N-Methyl-D-Aspartate Receptor Participation in Parkinson's Disease, a Neurodegenerative Disorder", <u>Annals of the N.Y. Acad of Sci.</u> , 765 : 327, 1995				
	24	HALE ET AL., "Low Dose Perphenazine and Levodopa/Carbidopa Therapy in a Patient with Parkinsonism and a Psychotic Illness", <u>J. of Nervous and Mental Health</u> , 168(5) : 312-314, 1980.				
	25	PERINI ET AL. "Trattamento con fluoperazina in un caso di allucinosi farmaco-indotta nel corso di terapia per morbo di Parkinson", <u>Gazzetta Medica Italiana</u> , 148(3) : 101-104, 1989.				

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.